Abstract
Until recently, the therapeutic options for patients suffering from active AS comprised NSAIDs and TNF inhibitor therapy. Although these are effective in a significant proportion of patients, not all patients respond and some are intolerant to these therapies. Therefore, there is a clear unmet treatment need in AS patients. This article reviews the evidence for targets currently being studied in AS. This includes the IL-12/23 inhibitor ustekinumab, the pan-Janus kinase inhibitor tofacitinib and the anti-IL-17A antibody secukinumab.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents / therapeutic use*
-
Health Services Needs and Demand
-
Humans
-
Piperidines / therapeutic use*
-
Pyrimidines / therapeutic use*
-
Pyrroles / therapeutic use*
-
Spondylitis, Ankylosing / drug therapy*
-
Translational Research, Biomedical
-
Ustekinumab / therapeutic use*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents
-
Piperidines
-
Pyrimidines
-
Pyrroles
-
tofacitinib
-
secukinumab
-
Ustekinumab